Special Issue "Advances in Vaccines for Substance Use Disorders"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: 31 October 2023 | Viewed by 64

Special Issue Editor

Dr. Colin N. Haile
E-Mail Website
Guest Editor
Department of Psychology & TIMES, University of Houston, Houston, TX 77204, USA
Interests: neuroscience; behavioral pharmacology; medication development; vaccines; immunology

Special Issue Information

Dear Colleagues,

Immunotherapeutic vaccines that target substances associated with use disorders in humans may represent a novel treatment strategy. The indicated treatments for opioid and nicotine use disorders are plagued by non-compliance and low efficacy, and currently, no treatments are approved for cocaine and methamphetamine use disorders. Vaccines for these and other substance use disorders trigger an immune response, generating antibodies against a specific drug.  The antibodies bind to the targeted substance and prevent it from entering the brain, sequestering it in systemic circulation. Eventually, the substance is eliminated from the body and produces no psychoactive effects.  The scope of this Special Issue includes vaccines, adjuvants, screening methods and evaluations of these formulations in different stages of development with the utilization of in vitro and in vivo models. The development of efficacious vaccines has the potential to provide much-needed therapeutic options for the treatment of substance use disorders. 

Dr. Colin N. Haile
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • vaccines
  • substance use disorder
  • immunotherapy
  • adjuvant
  • hapten
  • immunogenicity
  • antibody

Published Papers

This special issue is now open for submission.
Back to TopTop